{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T16:48:34Z","timestamp":1787676514588,"version":"build-2784847793"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T00:00:00Z","timestamp":1747267200000},"content-version":"vor","delay-in-days":14,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Else-Kr\u00f6ner-Fresenius Foundation","award":["2023_EKEA.193"],"award-info":[{"award-number":["2023_EKEA.193"]}]},{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Seasonal Influenza A\/B vaccination is routinely administered in patients with Multiple Myeloma (MM) given their disease-and therapy-associated immunosuppression and risk of infection. Previous data show poor seroconversion rates after one vaccination with an increase to\u2009~\u200960% after boosting while the impact of multiple lines of therapy remains unclear. Accordingly, we performed a retrospective single-center study assessing immune responses after single or prime-boosting vaccination in 71 patients with MM treated at our institution during the 2019\/20 season. Overall, 63.3% of patients with MM achieved sufficient responses after one or two Influenza A\/B vaccinations. In patients receiving a prime-boost approach, significantly higher serological titers but no significant increase in responder rates were observed after the boost vaccination. Complete or very good partial remission and no immunoparesis were identified as independent predictors of sufficient serological response by multivariate regression analysis and responders were characterized by high CD19<jats:sup>+<\/jats:sup> B-cell and CD4<jats:sup>+<\/jats:sup> T-cell counts. Patients achieving a sufficient response only after the prime-boost approach showed significantly shorter time since high-dose chemotherapy and autologous stem-cell transplantation (HDC-ASCT). Together, this study suggests that single vaccination against Influenza A\/B might be sufficient for patients with MM while a prime-boost approach might be necessary for patients with recent HDC-ASCT.\u00a0<\/jats:p>","DOI":"10.1007\/s00277-025-06367-1","type":"journal-article","created":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T03:27:01Z","timestamp":1747279621000},"page":"2813-2821","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immune responses after one versus two Influenza A\/B vaccinations in patients with multiple myeloma"],"prefix":"10.1007","volume":"104","author":[{"given":"Julius C.","family":"Enssle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonio","family":"Brinkschmidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"D\u00fcrrwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Zurmeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Steffen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Ullrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Oellerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Serve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"von Metzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,15]]},"reference":[{"key":"6367_CR1","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1002\/AJH.26590","volume":"97","author":"SV Rajkumar","year":"2022","unstructured":"Rajkumar SV (2022) Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97:1086\u20131107. https:\/\/doi.org\/10.1002\/AJH.26590","journal-title":"Am J Hematol"},{"key":"6367_CR2","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1128\/CVI.00021-11","volume":"18","author":"J Karlsson","year":"2011","unstructured":"Karlsson J, Andr\u00e9asson B, Kondori N et al (2011) Comparative study of immune status to infectious agents in elderly patients with multiple myeloma, Waldenstrom\u2019s macroglobulinemia, and monoclonal gammopathy of undetermined significance. Clin Vaccine Immunol 18:969\u2013977. https:\/\/doi.org\/10.1128\/CVI.00021-11","journal-title":"Clin Vaccine Immunol"},{"key":"6367_CR3","doi-asserted-by":"publisher","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","volume":"23","author":"BM Augustson","year":"2005","unstructured":"Augustson BM, Begum G, Dunn JA et al (2005) Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002\u2013Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 23:9219\u20139226. https:\/\/doi.org\/10.1200\/JCO.2005.03.2086","journal-title":"J Clin Oncol"},{"key":"6367_CR4","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/S00277-019-03621-1","volume":"98","author":"A Brioli","year":"2019","unstructured":"Brioli A, Klaus M, Sayer H et al (2019) The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey. Ann Hematol 98:713\u2013722. https:\/\/doi.org\/10.1007\/S00277-019-03621-1","journal-title":"Ann Hematol"},{"key":"6367_CR5","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1016\/S0140-6736(17)33293-2","volume":"391","author":"AD Iuliano","year":"2018","unstructured":"Iuliano AD, Roguski KM, Chang HH et al (2018) Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 391:1285\u20131300. https:\/\/doi.org\/10.1016\/S0140-6736(17)33293-2","journal-title":"Lancet"},{"key":"6367_CR6","doi-asserted-by":"publisher","unstructured":"Lafond KE, Porter RM, Whaley MJ et al (2021) Global burden of influenza-associated lower respiratory tract infections and hospitalizations among adults: A systematic review and meta-analysis. PLoS Med 18:. https:\/\/doi.org\/10.1371\/JOURNAL.PMED.1003550","DOI":"10.1371\/JOURNAL.PMED.1003550"},{"key":"6367_CR7","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1016\/S0140-6736(22)00982-5","volume":"400","author":"TM Uyeki","year":"2022","unstructured":"Uyeki TM, Hui DS, Zambon M et al (2022) Influenza Lancet 400:693\u2013706. https:\/\/doi.org\/10.1016\/S0140-6736(22)00982-5","journal-title":"Influenza Lancet"},{"key":"6367_CR8","doi-asserted-by":"publisher","unstructured":"Bitterman R, Eliakim-Raz N, Vinograd I et al (2018) Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database Syst Rev 2:. https:\/\/doi.org\/10.1002\/14651858.CD008983.PUB3","DOI":"10.1002\/14651858.CD008983.PUB3"},{"key":"6367_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/S41375-020-01016-0","volume":"35","author":"H Ludwig","year":"2021","unstructured":"Ludwig H, Boccadoro M, Moreau P et al (2021) Recommendations for vaccination in multiple myeloma: a consensus of the European Myeloma Network. Leukemia 35:31\u201344. https:\/\/doi.org\/10.1038\/S41375-020-01016-0","journal-title":"Leukemia"},{"key":"6367_CR10","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","volume":"9","author":"NS Raje","year":"2022","unstructured":"Raje NS, Anaissie E, Kumar SK et al (2022) Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the International Myeloma Working Group. Lancet Haematol 9:e143\u2013e161. https:\/\/doi.org\/10.1016\/S2352-3026(21)00283-0","journal-title":"Lancet Haematol"},{"key":"6367_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/BLOOD-2010-10-311217","volume":"117","author":"AJJ Barrett","year":"2011","unstructured":"Barrett AJJ (2011) Fighting the flu in multiple myeloma. Blood 117:1\u20132. https:\/\/doi.org\/10.1182\/BLOOD-2010-10-311217","journal-title":"Blood"},{"issue":"Suppl 2","key":"6367_CR12","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1002\/AJH.26766","volume":"98","author":"H Ludwig","year":"2023","unstructured":"Ludwig H, Kumar S (2023) Prevention of infections including vaccination strategies in multiple myeloma. Am J Hematol 98(Suppl 2):S46\u2013S62. https:\/\/doi.org\/10.1002\/AJH.26766","journal-title":"Am J Hematol"},{"key":"6367_CR13","doi-asserted-by":"publisher","first-page":"e285","DOI":"10.3324\/HAEMATOL.2014.116772","volume":"100","author":"M Hahn","year":"2015","unstructured":"Hahn M, Schnitzler P, Schweiger B et al (2015) Efficacy of single versus boost vaccination against influenza virus in patients with multiple myeloma. Haematologica 100:e285\u2013e288. https:\/\/doi.org\/10.3324\/HAEMATOL.2014.116772","journal-title":"Haematologica"},{"key":"6367_CR14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/J.CLML.2017.02.025","volume":"17","author":"AR Branagan","year":"2017","unstructured":"Branagan AR, Duffy E, Albrecht RA et al (2017) Clinical and Serologic Responses After a Two-dose Series of High-dose Influenza Vaccine in Plasma Cell Disorders: A Prospective, Single-arm Trial. Clin Lymphoma Myeloma Leuk 17:296-304.e2. https:\/\/doi.org\/10.1016\/J.CLML.2017.02.025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"6367_CR15","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.1016\/S0264-410X(00)00126-2","volume":"18","author":"LB Brydak","year":"2000","unstructured":"Brydak LB, Roszkowska-Blaim M, MacHala M et al (2000) Antibody response to influenza immunization in two consecutive epidemic seasons in patients with renal diseases. Vaccine 18:3280\u20133286. https:\/\/doi.org\/10.1016\/S0264-410X(00)00126-2","journal-title":"Vaccine"},{"key":"6367_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.virusres.2004.02.025","volume":"103","author":"C Hannoun","year":"2004","unstructured":"Hannoun C, Megas F, Piercy J (2004) Immunogenicity and protective efficacy of influenza vaccination. Virus Res 103:133\u2013138. https:\/\/doi.org\/10.1016\/j.virusres.2004.02.025","journal-title":"Virus Res"},{"key":"6367_CR17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1038\/SJ.BMT.1704870","volume":"35","author":"P Ljungman","year":"2005","unstructured":"Ljungman P, Engelhard D, de la C\u00e1mara R et al (2005) Vaccination of stem cell transplant recipients: recommendations of the Infectious Diseases Working Party of the EBMT. Bone Marrow Transplant 35:737\u2013746. https:\/\/doi.org\/10.1038\/SJ.BMT.1704870","journal-title":"Bone Marrow Transplant"},{"key":"6367_CR18","doi-asserted-by":"publisher","unstructured":"Terpos E, Gavriatopoulou M, Ntanasis-Stathopoulos I et al (2021) The neutralizing antibody response post COVID-19 vaccination in patients with myeloma is highly dependent on the type of anti-myeloma treatment. Blood Cancer J 11:. https:\/\/doi.org\/10.1038\/S41408-021-00530-3","DOI":"10.1038\/S41408-021-00530-3"},{"key":"6367_CR19","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/BJH.18079","volume":"197","author":"T Terao","year":"2022","unstructured":"Terao T, Naduka T, Ikeda D et al (2022) Depletion of CD38-positive regulatory T cells by anti-CD38 monoclonal antibodies induces a durable response to SARS-CoV-2 vaccination in patients with plasma cell dyscrasia. Br J Haematol 197:417\u2013421. https:\/\/doi.org\/10.1111\/BJH.18079","journal-title":"Br J Haematol"},{"key":"6367_CR20","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1182\/BLOODADVANCES.2020003857","volume":"5","author":"H Parmar","year":"2021","unstructured":"Parmar H, Gertz M, Anderson EI et al (2021) Microenvironment immune reconstitution patterns correlate with outcomes after autologous transplant in multiple myeloma. Blood Adv 5:1797\u20131804. https:\/\/doi.org\/10.1182\/BLOODADVANCES.2020003857","journal-title":"Blood Adv"},{"key":"6367_CR21","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/J.CCELL.2022.05.003","volume":"40","author":"JC Enssle","year":"2022","unstructured":"Enssle JC, Campe J, B\u00fcchel S et al (2022) Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma. Cancer Cell 40:587\u2013589. https:\/\/doi.org\/10.1016\/J.CCELL.2022.05.003","journal-title":"Cancer Cell"},{"key":"6367_CR22","doi-asserted-by":"publisher","unstructured":"Enssle JC, Campe J, Moter A et al (2024) Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients. Leukemia 38:. https:\/\/doi.org\/10.1038\/S41375-023-02070-0","DOI":"10.1038\/S41375-023-02070-0"},{"key":"6367_CR23","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1182\/BLOOD.2021013429","volume":"139","author":"JC En\u00dfle","year":"2022","unstructured":"En\u00dfle JC, Campe J, Schwenger A et al (2022) Severe impairment of T-cell responses to BNT162b2 immunization in patients with multiple myeloma. Blood 139:137\u2013142. https:\/\/doi.org\/10.1182\/BLOOD.2021013429","journal-title":"Blood"},{"key":"6367_CR24","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1002\/AJH.26752","volume":"98","author":"MV Dhodapkar","year":"2023","unstructured":"Dhodapkar MV (2023) The immune system in multiple myeloma and precursor states: Lessons and implications for immunotherapy and interception. Am J Hematol 98:S4\u2013S12. https:\/\/doi.org\/10.1002\/AJH.26752","journal-title":"Am J Hematol"},{"key":"6367_CR25","doi-asserted-by":"publisher","unstructured":"Coffey DG, Maura F, Gonzalez-Kozlova E et al (2023) Immunophenotypic correlates of sustained MRD negativity in patients with multiple myeloma. Nat Commun 14:1 14:1\u201312. https:\/\/doi.org\/10.1038\/s41467-023-40966-8","DOI":"10.1038\/s41467-023-40966-8"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06367-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-025-06367-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-025-06367-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T06:37:51Z","timestamp":1749105471000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-025-06367-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["6367"],"URL":"https:\/\/doi.org\/10.1007\/s00277-025-06367-1","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"26 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"I.M. received honoraria for advising Pfizer, Sanofi, BMS, GSK, Amgen, Janssen, Takeda and AstraZeneca. B.S. received support for attending meetings and\/or travel from Abbvie and Jazz Pharmaceuticals. E.U. received honoraria for advising Phialogics and BMS. All other authors declare no competing interests to the present study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}